UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.704

Sortiert nach

Rifabutin: where do we stand in 2016?

Journal of antimicrobial chemotherapy, 2016-07, Vol.71 (7), p.1759-1771

2016

Volltextzugriff (PDF)

Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model

British journal of clinical pharmacology, 2023-03, Vol.89 (3), p.1216-1221

2023

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

Journal of acquired immune deficiency syndromes (1999), 2013-01, Vol.62 (1), p.21

2013

Volltextzugriff (PDF)

Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis

Drug design, development and therapy, 2016-01, Vol.10, p.2467-2475

2016

Volltextzugriff (PDF)

Genome-Driven Discovery of Hygrocins in Streptomyces rapamycinicus

Journal of natural products (Washington, D.C.), 2024-05, Vol.87 (5), p.1321-1329

2024

Volltextzugriff (PDF)

Microencapsulated Solid Lipid Nanoparticles as a Hybrid Platform for Pulmonary Antibiotic Delivery

Molecular pharmaceutics, 2017-09, Vol.14 (9), p.2977-2990

2017

Volltextzugriff (PDF)

Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies

International journal of pharmaceutics, 2016-01, Vol.497 (1-2), p.199-209

2016

Volltextzugriff (PDF)

Prins‐Type Macrocyclizations as an Efficient Ring‐Closing Strategy in Natural Product Synthesis

Angewandte Chemie (International ed.), 2010-11, Vol.49 (45), p.8316-8326

2010

Volltextzugriff (PDF)

A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis

Nature communications, 2022-08, Vol.13 (1), p.4455-4455, Article 4455

2022

Volltextzugriff (PDF)

HIV ile Enfekte Bireyde CMV Retiniti ve Lenf Nodunda ARB Pozitifligi

Mediterranean journal of infection, microbes & antimicrobials, 2024-01, Vol.13, p.314

2024

Volltextzugriff (PDF)

Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin

Journal of aerosol medicine and pulmonary drug delivery, 2016-04, Vol.29 (2), p.179

2016

Volltextzugriff (PDF)

Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections

Drug discovery today, 2021-09, Vol.26 (9), p.2099-2104

2021

Volltextzugriff (PDF)

Systematic review of drug–drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management

Pharmacotherapy, 2022-04, Vol.42 (4), p.343-361

2022

Volltextzugriff (PDF)

Activating a Cryptic Ansamycin Biosynthetic Gene Cluster To Produce Three New Naphthalenic Octaketide Ansamycins with n‑Pentyl and n‑Butyl Side Chains

Organic letters, 2015-08, Vol.17 (15), p.3706-3709

2015

Volltextzugriff (PDF)

New Ansamycin Derivatives Generated by Simultaneous Mutasynthesis

Organic letters, 2015-02, Vol.17 (3), p.556-559

2015

Volltextzugriff (PDF)

Ansalactams B–D Illustrate Further Biosynthetic Plasticity within the Ansamycin Pathway

Organic letters, 2016-05, Vol.18 (9), p.2256-2259

2016

Volltextzugriff (PDF)

Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment

Drug development and industrial pharmacy, 2019-08, Vol.45 (8), p.1313-1320

2019

Volltextzugriff (PDF)

C15-methoxyphenylated 18-deoxy-herbimycin A analogues, their in vitro anticancer activity and heat shock protein 90 binding affinity

Bioorganic & medicinal chemistry letters, 2016-09, Vol.26 (17), p.4287-4291

2016

Volltextzugriff (PDF)

The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori

The Journal of infectious diseases, 2022-12, Vol.226 (Suppl 5), p.S479-S485

2022

Volltextzugriff (PDF)

Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan

International journal of infectious diseases, 2024-01, Vol.138, p.25-28

2024

Volltextzugriff (PDF)

Rifabutin Is Active against Mycobacterium abscessus Complex

Antimicrobial agents and chemotherapy, 2017-06, Vol.61 (6)

2017

Volltextzugriff (PDF)

Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting

Journal of drug targeting, 2009-12, Vol.17 (10), p.777-787

2009

Volltextzugriff (PDF)

Fäkales Resistogramm für Helicobacter pylori

Gastro-News, 2022-08, Vol.9 (4), p.22-23

H. Waggershauser, Constanze

2022

Volltextzugriff (PDF)

Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population

Gastroenterology (New York, N.Y. 1943), 2021-05, Vol.160 (6), p.2181-2183.e1

2021

Volltextzugriff (PDF)

1 – 25 von 1.704

Suche als RSS-Feed

Aktive Filter

ThemaBenzoquinones

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.355)
Mit Volltextzugriff
(1.237)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.157)
Life Sciences & Biomedicine
(1.071)
Rifabutin
(1.026)
Humans
(899)
Male
(392)
Rifabutin - Therapeutic Use
(391)
Pharmacology & Pharmacy
(383)
Biological And Medical Sciences
(366)
Infectious Diseases
(362)
Medical Sciences
(346)
Female
(345)
Microbiology
(333)
Adult
(291)
Pharmacology. Drug Treatments
(285)
Tuberculosis
(274)
Rifabutin - Pharmacology
(250)
Drug Therapy, Combination
(228)
Aids/hiv
(227)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(213)
Middle Aged
(212)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(18)

Menü

Weitere Dienste

Einstellungen

Rifabutin: where do we stand in 2016?

Drug–drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis

Genome-Driven Discovery of Hygrocins in Streptomyces rapamycinicus

Microencapsulated Solid Lipid Nanoparticles as a Hybrid Platform for Pulmonary Antibiotic Delivery

Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies

Prins‐Type Macrocyclizations as an Efficient Ring‐Closing Strategy in Natural Product Synthesis

A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis

HIV ile Enfekte Bireyde CMV Retiniti ve Lenf Nodunda ARB Pozitifligi

Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin

Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections

Systematic review of drug–drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management

Activating a Cryptic Ansamycin Biosynthetic Gene Cluster To Produce Three New Naphthalenic Octaketide Ansamycins with n‑Pentyl and n‑Butyl Side Chains

New Ansamycin Derivatives Generated by Simultaneous Mutasynthesis

Ansalactams B–D Illustrate Further Biosynthetic Plasticity within the Ansamycin Pathway

Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment

C15-methoxyphenylated 18-deoxy-herbimycin A analogues, their in vitro anticancer activity and heat shock protein 90 binding affinity

The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori

Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan

Rifabutin Is Active against Mycobacterium abscessus Complex

Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting

Fäkales Resistogramm für Helicobacter pylori

Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam

Aktive Filter

Suchergebnisse filtern